Fragile Histidine Triad Gene Inactivation in Lung Cancer
The European Early Lung Cancer Project

Carla Verri1*, Luca Rozz*, Davide Conte†, Triantafillos Liloglou‡, Anna Livio*, Aurelien Vesin§, Alessandra Fabbri‖, Francesca Andriani‖, Christian Brambilla†, Luca Tavecchio†, Giuseppe Calarco‖, Elisa Calabro‖, Andrea Mancini‖, Diego Tosi†, Paolo Bossi‖, John K. Field‡, Elisabeth Brambilla§, Gabriella Sozzi1*, and the EUELC Consortium‡

1Department of Experimental Oncology; 2Department of Pathology; 3Department of Thoracic Surgery; 4Department of Endoscopy; 5Department of Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; 6University of Liverpool, Division of Surgery & Oncology, Liverpool, United Kingdom; and 7Department of Pathology, INSERM U823, Albert Bonniot Institute, Grenoble, France

Rationale: Fragile histidine triad (FHIT) is a tumor suppressor gene involved in the pathogenesis of lung cancer.

Objectives: The purpose of this study was to investigate the different molecular alterations leading to the inactivation of FHIT gene function and to validate their use as biomarkers of risk for progression of the disease in patients belonging to the multicentric European study for the Early detection of Lung Cancer (EUELC) who were resected for early-stage lung tumors.

Methods: FHIT immunostaining was performed on 305 tumor samples. The methylation status of FHIT promoter was assessed by nested methylation-specific polymerase chain reaction (MSP-PCR) in 232 tumors and 225 normal lung samples of which a subset of 187 patients had available normal/tumor DNA pairs. Loss of heterozygosity (LOH) at the FHIT locus was analyzed in 202 informative cases by D3S1300 and D3S1234 microsatellite markers.

Measurements and Main Results: Lost or reduced FHIT expression was found in 36.7 and 75.7% of the tumor samples, respectively. Methylation of the FHIT promoter was found in 36.7% of tumor and 32.7% of normal lung samples, whereas LOH was detected in 61.9% of the tumors. A strong association with complete loss of FHIT expression was present when methylation and LOH were analyzed together (P = 0.0064). Loss of FHIT protein expression was significantly more frequent in squamous cell carcinoma histotype (P < 0.0001) and in smokers (P = 0.008). FHIT methylation in normal lung was associated with an increased risk of progressive disease (OR, 2.27; P = 0.0415).

Conclusions: Our results indicate that different molecular mechanisms interplay to inactivate FHIT expression and support the proposition that FHIT methylation in normal lung tissue could represent a prognostic marker for progressive disease.

Keywords: lung cancer; FHIT gene; methylation; prognostic biomarker

Lung cancer is one of the most common malignancies in the world and represents the leading cause of cancer-related deaths in industrialized countries. The overall 5-year survival rate for lung cancer is less then 15% largely due to the late stage at which most patients are diagnosed. Because survival of patients surgically resected for early-stage lung cancer is variable, the detection of additional prognostic parameters could be of importance to better predict the outcome of the disease and to offer the optimal therapeutic treatment to the patients.

Fragile histidine triad (FHIT) is a tumor suppressor gene that spans the FRAB3B common fragile site at chromosome 3p14.2 and is frequently altered in lung cancer. The FHIT gene function is inactivated by different biological mechanisms as promoter methylation and loss of heterozygosity at the FHIT locus.

What This Study Adds to the Field

The association between FHIT methylation in normal tissue and prognosis suggest that FHIT methylation in normal lung could represent a prognostic marker for early recurrence.

(Received in original form July 24, 2008; accepted in final form December 17, 2008)

* These authors contributed equally to this article.
† These authors are senior coauthors.
‡ A listing of the members of the EUELC Study Group can be found at the end of this article.

Supported by European Community (V shared-cost RTD action) grants and by the Associazione Italiana Ricerca Cancro (AIRC) and Lega Italiana Lotta Tumori (LILT) to C.S. and by the Italian Ministry of Health (Ricerca Finalizzata). C.V. is the recipient of a fellowship from AIRC.

Correspondence and requests for reprints should be addressed to Gabriella Sozzi, Ph.D., Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Via Venezian 1, 20133 Milan, Italy. E-mail: gabriella.sozzi@istitutotumori.mi.it

This article has an online data supplement, which is accessible from this issue’s table of contents at www.atsjournals.org

Am J Respir Crit Care Med Vol 179, pp 396–401, 2009
Originally Published in Press as DOI: 10.1164/rcrm.200807-1153OC on December 18, 2008
Internet address: www.atsjournals.org
clinical outcome of the patients was studied in an attempt to provide a molecular tool useful for identifying individuals at higher risk of relapse or second primary tumors. Some of the results of these studies have been previously reported in the form of an abstract (13).

**METHODS**

**Study Population**

A cohort of individuals with a diagnosis of early stage (I-II) lung cancer and who underwent surgical resection was included in the European study for the Early detection of Lung Cancer (EUELC). The patients were recruited before surgery in 12 cancer centers throughout Europe from 2002 to 2006 and were subsequently followed-up every 6 months for the duration of this study. Inclusion criteria are detailed in the online supplement. Tissue and biological specimens collected were sent from all the recruiting centers to the centralized European Bronchial Tissue Bank (EBTB) located in Liverpool, UK. A web-based database was set up (MACRO) to hold all clinical, epidemiological and follow-up data, as well as information on tissue and biological specimens collected in the study.

From the EUELC cohort of 913 patients, 359 cases were selected for this analysis on the basis of the availability of material for molecular analyses and clinical information for an average follow-up period of 18 months. To assess the molecular risk factors for disease progression, the patients were classified in two groups: those with early relapse, recurrence, metastasis, or second primary lung cancer (with a disease-free period of 6 mo after surgery) were defined as progressive disease group (PD); patients that remained tumor-free during the study were defined as disease-free group (DF). The characteristics of study population are summarized in Table 1.

**Tissues Collection and DNA Extraction**

All tissues were freshly collected during surgery and stored at −80°C in the EBTB bank. As a routine practice for TNM staging nontumor lung specimens are sampled at a distance from the tumor to guarantee that the tissues are free from cancerous cells, atelectasis, and obstructive pneumonia (14).

Frozen normal and tumor tissues were cut into 20 × 4 μm sections. Tumor sections were stained with H&E and microscopically viewed for tumor cell content. Excessive normal tissue was removed to ensure 80% or more tumor cell content.

For LOH analysis, normal control DNA was extracted from peripheral blood lymphocytes. DNA extraction from tissue samples and lymphocytes was performed using DNeasy 96 Blood and Tissue kit (Qiagen, Studio City, CA) following supplier’s protocol.

**Immunohistochemistry**

Immunohistochemical staining was performed on formalin fixed paraffin-embedded biopsies with the rabbit anti-FHIT antibody (18-0219, Zymed Laboratories, South San Francisco, CA) at a dilution of 1:100 on Ventana automated immunostainer (Ventana, Tucson, AZ). For antigen retrieval, 5 minutes of microwave heating in ethylenediaminetetraacetic acid buffer was repeated twice. FHIT immunoreactivity was classified according to a score obtained by multiplying two parameters: the percentage of positive cells (from 0 to 100) by the intensity mean level (from 0 to 3) for a global score of 0 to 300. Normal bronchial and alveolar epithelial cells, used as internal controls, showed a strong FHIT expression score of 200 (score 3) or greater. An extensive loss of FHIT expression immunostaining was considered for tumors with scores of 50 (score 1) or less, and reduced protein expression was considered for scores of 50 to 200 (score 2). For the purpose of statistical comparisons, a score of 0 versus 1–3 or a score of 0–1 versus 2–3, was used to obtain homogeneity of the classes and to achieve a meaningful biological assessment.

**Bisulphite Conversion and Methylation-specific Polymerase Chain Reaction**

The methylation status of the promoter region of the FHIT gene was evaluated by methylation-specific polymerase chain reaction (MSP-PCR) after DNA modification with sodium bisulphite (EZ DNA Methylation Gold Kit, Zymo Research, Orange, CA (15). MSP analysis for the FHIT gene investigates the genomic areas that represent the best targets for functionally relevant methylation identified into intron 1 (see online supplement for further details on Methods).

**LOH Analysis**

Allelic LOH analysis at the FHIT locus on 3p14.2 was performed by studying the combination of two microsatellite alterations, D3S1300 and D3S1234. Thirty nanograms of DNA from tumor tissue and matching lymphocytes were used for the analysis, as previously reported (16, 17).

**Statistical Analysis**

Fisher exact test was performed to test independence of variables. Distributions of demographic variables (including sex and smoking status) between PD cases and DF controls were evaluated by chi-square test. Differences between PD cases and DF controls in age and self-reported pack-years were tested using the Student’s t test. When the data distribution significantly deviated from normal, the Wilcoxon rank sum test was performed. Odds ratios (OR) and 95% confidence interval (CI) were calculated as estimates of relative risk. Odds ratios associated with each risk factor were calculated using the conditional logistic regression model while adjusting for confounders. A test for trends was performed by coding the categories in successive integers and using the likelihood ratio test statistics with one degree of freedom. Statistical analyses were performed with the statistical analysis package SAS for Windows, version 8.02 (SAS Institute, Cary, NC).

Risk estimation for disease progression according to different variables was initially performed on a set of patients with a 1:1 ratio of PD:DF (n = 176, first set). To achieve optimal matching in assessing epidemiological and molecular risk factors for disease progression in the final dataset (n = 359), the conditional logistic regression for matching design was used. PD cases and DF controls were matched with a 1:2 ratio using the SAS language procedure (see online supplement). Patients were matched on follow-up times (at least as long as the event time for PD subjects) and also on center, sex, age (≤ 26 y), histological subtypes, and N stage.

**RESULTS**

**Biological Mechanisms of Inactivation of FHIT Gene and Their Correlation with FHIT Protein Expression**

From the series of 359 cases originally selected for biomarker analysis the number of samples analyzed in each FHIT assay...
was limited to subsets on the basis of specimen type availability in the EBTB bank. Thus, immunohistochemistry (IHC) analysis of FHIT protein expression was performed in 305 cases with formalin-fixed, paraffin-embedded (FFPE) tissue, DNA for methylation analysis was available from 232 tumor and 225 normal lung tissues, while LOH analysis was performed in a subset of 228 tumor-normal pairs.

**FHIT protein expression.** Immunostaining was performed on sections from 305 paraffin embedded tumor samples (Figure 1). Reduced protein expression (a score of 0–2) was found in the majority (75.7%) of the tumor samples, whereas extensive loss of FHIT expression (a score of 0–1) was also detected in a significant subset (36.7%). Frequencies for each score of FHIT expression are reported in Table 2. Loss of FHIT protein expression (a score of 0–1) was significantly higher ($P < 0.0001$) in squamous cell carcinoma (82/137, 59.9%) than in adenocarcinoma (30/168, 17.9%), whereas expression was not associated with pathological tumor-node-metastasis (pTNM) stage. A significant association was observed between expression and smoking habits: loss of FHIT expression was significantly greater ($P = 0.008$) in former and current smokers (221/287, 77%) than in never-smokers (6/14, 42.9%).

**FHIT promoter methylation in tumor and normal tissues.** PCR amplification was successful, as assessed by the presence of a product in the “unmethylated” reaction, in 229/232 tumor tissues and in 208/225 normal tissues. MSP demonstrated the presence of methylated FHIT alleles in 36.7% (84/229) tumor tissues and in 32.7% (68/208) of the normal adjacent tissues examined, indicating a marginal but not significant increase of FHIT methylation frequency in tumor tissue ($P = 0.0749$). In the subset of 187 patients with paired normal and tumor tissue successfully analyzed we observed methylation in both tissues in 15% (28/187) of the pairs, whereas 46% (86/187) of the pairs presented only unmethylated alleles (Figure 2). Although 21% (39/187) of the pairs demonstrated FHIT methylation only in tumor DNA, perhaps the most intriguing group was the remaining 18% (34/187) that included cases with methylation restricted to normal lung samples. Among the cases with methylation in normal tissue 45.2% (28/62) showed methylation also in the corresponding tumor sample, whereas the remaining 54.8% (34/62) was unmethylated in the matching tumor DNA (Table 3). No significant association was observed between FHIT methylation in tumor and normal samples or between FHIT methylation status in normal and tumor samples and clinical-pathological variables like smoking habits, tumor stage, and histology.

**Genomic instability of FHIT locus.** LOH at the FHIT locus at 3p14.2 was analyzed in 228 normal-tumor paired DNAs combining two microsatellite markers: D3S1300 (intron 5) and D3S1234 (intron 7). The analysis revealed LOH at D3S1234 in 59% (92/156) of the informative (heterozygous) cases, while for D3S1300 56.2% (59/105) of the informative cases showed LOH. The combined analysis of the two microsatellites, D3S1300 and D3S1234, resulted in 202 informative cases of which 61.9% (125/202) showed LOH at the FHIT locus for at least one microsatellite. As expected, there was a high frequency of LOH coincidence between these two markers. In particular, 71.2% (42/59) of “double informative samples” demonstrated LOH at both loci (Fisher’s exact test, $P = 0.001$), which is in accordance with previous observations that deletions affecting the FHIT locus are usually large and span the entire gene.

**FHIT methylation, FHIT LOH, and loss of expression by immunostaining.** To investigate the relationship between FHIT methylation with the potential underlying genetic (LOH at FHIT locus) and epigenetic (promoter methylation) determinants we comparatively analyzed data for these parameters. FHIT methylation and LOH resulted as independent events ($P = 1.0000$), confirming the notion that these two types of alterations represent alternative molecular mechanisms of FHIT gene inactivation.

A borderline association ($P = 0.0577$) was observed between FHIT methylation and complete loss of FHIT protein expression (a score of 0). Among the methylation-negative samples, however, 31 of 135 (23%) samples gave negative immunostaining, suggesting that mechanisms of gene silencing other than methylation should coexist.

LOH was significantly ($P = 0.0182$) associated with loss of FHIT expression (a score of 0), further supporting the relevant role of this type of molecular event in inactivating FHIT function.

The occurrence of both methylation and/or LOH were highly associated with loss of FHIT protein expression ($P = 0.0064$) indicating that genetic and epigenetic events concur to functionally impair FHIT expression (Table 4).

**FHIT Status and Risk for Disease Progression**

The association between FHIT alterations and the risk of progressive disease was assessed considering the clinical outcome of patients with a disease-free period of at least 6 months after surgery. Patients were classified in two groups: those with early relapse, recurrence, metastasis, or second primary lung cancer (with a disease-free period of 6 mo after surgery) were defined as progressive disease group (PD); patients that remained tumor-free during the study were defined disease-free group (DF). We performed a preliminary analysis in a first set of 176 patients and subsequently extended the analysis to a larger dataset of 359 patients. Only 28 patients of the first group were not included in the final dataset.

**Progressive disease risk in the first set of patients.** In the first set of 176 patients, PD and DF groups were similarly represented.

![Figure 1](image-url). Fragile histidine triad (FHIT) immunostaining in lung tumor tissue. Representative immunohistochemical analysis at magnification 20×. (A and F) Loss of FHIT expression in an adenocarcinoma contrasting with the high expression of FHIT in bronchial epithelial cells. (B, C, and D) Strong, medium, and low FHIT expression in a squamous cell carcinoma, respectively. (D) Strong FHIT expression in the bronchioalveolar component of an adenocarcinoma.
with 86 (48.9%) PD (cases) and 90 (51.1%) DF (controls) patients. All characteristics of this set of individuals are reported in Table 1. Statistical analysis for assessing the risk of progressive disease was performed according to epidemiological and clinical characteristics and molecular biological markers. No association was detected between FHIT methylation, LOH, or loss of protein expression in tumors and prognosis.

We found a strong association between FHIT methylation status in normal tissue, evaluated in 116 cases, and the progression of disease (OR, 4.30; P = 0.0001). Moreover, the association remained significant after adjustment for smoking duration, life condition, and primary tumor size (OR, 7.39; P = 0.02).

Progressive disease risk in the final set of patients. The analyses were then expanded to a larger dataset of 359 patients having similar epidemiological and clinical characteristics. A conditional logistic regression using matching design was performed for the analysis of risk factors for progressive disease. Each PD case was matched with two DF controls, as described in METHODS. The matching was feasible for only 296 patients, where PD and DF patients represented 31.8 and 68.2% of the entire dataset, respectively. The distribution of clinical-demographic features was homogenous in PD and DF groups with the exception of the tumor stage. In the DF group 74.5% of tumors were stage I versus 47.4% in the PD group.

FHIT methylation in normal lung, evaluated in this cohort of 168 patients (Table 3), was significantly associated with an increased risk of PD (OR, 2.27; P = 0.0415), and the association remained significant after adjustment for tumor size (OR, 2.28; P = 0.0435). Analysis according to histological subtypes showed that FHIT methylation in normal lung was especially associated with an increased risk of having disease progression in patients with adenocarcinoma (OR, 3.54; P = 0.0509).

Matching design analysis of this larger dataset did not indicate a significant association between FHIT status in tumor tissue and prognosis.

DISCUSSION

The overall goal of the EUELC project was to detect molecular-pathological abnormalities in early-stage primary lung tumors that would be useful for the identification of individuals at risk of developing second primary lung cancers, metastasis, and recurrences.

EUELC was one of the largest planned early lung cancer projects in Europe, and it enabled the Partners to establish protocols for assessing molecular biomarkers in early lung cancer with the view that such biomarkers maybe used in future early detection programs in Europe.

The purpose of the present study was to investigate the different types of molecular alterations leading to the inactivation of FHIT gene function and to validate their use as biomarkers of risk for progression of the disease in high-risk individuals.

Several studies have reported the central role of the FHIT gene in lung tumorigenesis, and loss of protein expression has been described in several human neoplasms of epithelial origin including lung cancer (9, 18–20). Because of the variety and complexity of the molecular and epigenetic changes affecting the FHIT gene, a loss or reduced FHIT protein expression, as detected by immunohistochemistry, was suggested as the most reliable test for detecting FHIT gene alterations. Previous studies already showed that epigenetic events could impair FHIT gene function in lung tumors. FHIT intron 1 CpG islands were found methylated in 38% of lung squamous cell carcinomas and 57% of breast cancer DNAs and also in nonneoplastic adjacent mammary tissues (14%) and lung tissues (8%) (21). In lung squamous cell carcinoma and breast tumors, an association between methylation of FHIT promoter and protein expression was reported, confirming a previous study that showed a significant association between FHIT methylation status and loss of FHIT expression by Northern Blot and immunostaining in lung and breast cancer cell lines and primary tumors (10). In a small study of 30 locally advanced (stage III) lung carcinomas, no association was observed between FHIT LOH and loss of FHIT mRNA and protein expression, whereas methylation of the FHIT promoter correlated significantly with loss of FHIT expression at the transcript level (22).

However, previous studies have not addressed how epigenetic and genetic mechanisms interplay to inhibit FHIT protein expression and inactivate FHIT gene function, nor have they examined their association with prognosis using a large sample of lung cancer patients.

To dissect the molecular mechanisms leading to FHIT gene inactivation we investigated the relationship among the various alterations of the FHIT gene: allelic losses, promoter methylation, and FHIT protein expression. The high frequency of FHIT genetic, epigenetic, and protein alterations detected in this large

![Table 2. FHIT Protein Expression](image)

<table>
<thead>
<tr>
<th>Expression Score</th>
<th>Tumors (n = 305)</th>
<th>SCC (n = 137)</th>
<th>ADC and Other (n = 168)</th>
<th>P Value</th>
<th>Never (n = 14)</th>
<th>Former or Current (n = 287)</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>80 (26.2)</td>
<td>82 (59.9)</td>
<td>30 (17.9)</td>
<td>P &lt; 0.0001</td>
<td>6 (42.9)</td>
<td>221 (77)</td>
<td>P = 0.008</td>
</tr>
<tr>
<td>1</td>
<td>32 (10.5)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>119 (39.0)</td>
<td>55 (40.1)</td>
<td>138 (82.1)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>74 (24.3)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Definition of abbreviations: ADC = adenocarcinoma; SCC = squamous cell carcinoma.
TABLE 3. METHYLATION IN NORMAL LUNG TISSUE

<table>
<thead>
<tr>
<th>Methylation Status</th>
<th>Normal Tissue (n = 208)*</th>
<th>Tumor Tissue†</th>
<th>FHIT Risk for Disease Progression‡</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Unmethylated</td>
<td>Methylated</td>
<td>Unmethylated</td>
</tr>
<tr>
<td>Unmethylated</td>
<td>140 (67.3)</td>
<td>39/125 (31.2)</td>
<td>86/125 (68.8)</td>
</tr>
<tr>
<td>Methylated</td>
<td>68 (32.7)</td>
<td>28/62 (45.2)</td>
<td>34/62 (54.8)</td>
</tr>
</tbody>
</table>

Definition of abbreviations: CI = confidence interval; DF = disease-free group; FHIT = fragile histidine triad; OR = odds ratio; PD = progressive disease
Values are n (%) unless otherwise indicated.
* Only successfully amplified samples in methylation-specific assay.
† Patients with paired normal and tumor tissue successfully analyzed.
‡ DF are patients that remained tumor free during the study and PD are patients with progression of disease.

A sample of early-stage lung tumors further supports a primary role of FHIT in lung carcinogenesis. Moreover, loss of protein expression was distinctive of smoke-related tumors and particularly related to squamous cell carcinoma.

A strong relationship among the combination of LOH and methylation with FHIT protein expression was detected in this sample. This association indicates that the mechanism of FHIT gene inactivation consists of both deletions and methylation events that contribute to the functional loss of expression. The lack of statistical association between LOH and methylation suggests that these two events independently affect FHIT expression.

So far no studies have analyzed the effects of FHIT promoter hypermethylation in normal lung as a prognostic factor, whereas cohypermethylation of p16 and FHIT promoters in tumor tissue in 335 stage I NSCLC was associated with an increased risk of recurrence and poor recurrence-free survival after surgery (23).

We observed a similar frequency of methylation in normal lung and tumor tissue; however, 54.8% of patients with methylated FHIT in normal lung tissue lacked methylation in the corresponding tumor. This is not surprising because evidence supports, at a molecular level, an independent origin of multiple preneoplastic and neoplastic lung lesions (24, 25).

The high frequency of FHIT methylation detected in normal lung tissue of the patients in our study suggests that this type of FHIT alteration is an early event in lung carcinogenesis that likely reflects an early smoke-induced epigenetic damage. Moreover, the finding that FHIT methylation in normal lung was associated with an increased risk of progressive disease strongly suggests that the continuous exposure to tobacco smoke creates a “permissive” environment of damaged tissue (“field cancerization” effect) and that additional genetic damage could trigger the transformation process.

Recent data also indicate that extensive DNA damage, manifested through double strand-breaks, could in part be responsible for the acquisition of aberrant gene promoter methylation during lung carcinogenesis. In particular a diminished DNA repair capacity was found to be associated with an increased methylation index in sputum from persons at risk for lung cancer (26), supporting the hypothesis that methylation in normal lung might also reflect inability to repair DNA breaks induced by tobacco injury and therefore be linked to increased cancer risk.

Our finding is in agreement with previous reports showing that the ability to identify extensive or specific patterns of genetic changes in normal and preneoplastic tissues or sputum samples, may provide new methods for assessing the risk in smokers of developing invasive primary or recurrent lung cancer (27, 28).

Recently, gene-expression profiling studies in noncancerous hepatic tissue, and subsequently in noncancerous lung tissue of patients with early-stage adenocarcinoma, have reported a cytokine gene expression signature associated with a poor prognosis. These findings showed how noncancerous tissues could be suitable specimens to identify prognostic markers for patients who are at high risk of recurrence or metastasis (29, 30).

Thus, the final analysis on the complete dataset confirmed the association between FHIT methylation in normal tissue and early recurrence that was already detected in a preliminary analysis on a smaller set. A statistical trend, although not significant because of the limited number of events (n = 23), was observed between methylation status in normal lung, particularly in patients with adenocarcinoma, and development of secondary primary tumors of the lung during follow-up of the patients.

These results, if validated in larger studies, support the proposition that FHIT methylation in normal lung tissue could represent a prognostic marker for progressive disease, and particularly for assessment of the risk of early recurrence after surgery.

In conclusion, this multicentric effort of establishing a centralized European lung tissue bank has facilitated the collection and sharing of large series of biological specimens and could prove to be a useful approach to reliably study the role of a number of different biomarkers with relevance for lung cancer prognosis or early detection.

Conflict of Interest Statement: None of the authors has a financial relationship with a commercial entity that has an interest in the subject of this manuscript.

Acknowledgment: The authors thank all partners of EUELC Consortium and the coordinator, Professor John Field.

European Early Lung Cancer (EUELC) Study Group: Christian Brambilla (INSERM U823, Albert Bonniot Institute, Grenoble, France); Yves Martinet (Central Hospitalier Universitaire de Nancy, France); Frederik B. Thunnissen (Canisius Hospitalier Universitaire de Nancy, France);
References


